Cancer deaths expected to rise to over 18 million in 2050—an increase of nearly 75% from 2024, study forecasts
The Lancet
- Globally, the number of new cancer cases has more than doubled since 1990 to 18.5 million in 2023; whilst the number of cancer deaths increased 74% to 10.4 million (both excluding non-melanoma skin cancers)—with the majority of people affected living in low- and middle-income countries.
- Over 40% of cancer deaths globally are linked to 44 modifiable risk factors including tobacco use, an unhealthy diet, and high blood sugar—presenting an opportunity for prevention.
- The number of new cancer cases worldwide are predicted to rise 61% over the next 25 years to 30.5 million in 2050; and the annual global cancer death toll forecast to increase by nearly 75% to 18.6 million—mostly driven by population growth and increasingly ageing populations.
- Although global rates for cancer deaths (when adjusted for age) have decreased, this is not the case for some low- and middle-income countries where rates, as well as numbers, are on the rise.
- To meet the challenge of the growing number of cancer cases and deaths, the authors say it is imperative that greater efforts are made by policymakers, governments, and agencies to prevent, diagnose, and treat cancer at the country, regional, and global levels.
There has been a rapid increase in the global number of cancer cases and deaths between 1990 and 2023, despite advances in cancer treatment and efforts to tackle cancer risk factors over that same time period. Without urgent action and targeted funding, 30.5 million people are forecast to receive a new cancer diagnosis and 18.6 million are expected to die from cancer in 2050—with over half of new cases and two-thirds of deaths occurring in low- and middle-income countries (LMICs), according to a major new analysis from the Global Burden of Disease Study Cancer Collaborators, published in The Lancet.
While the overall number of cancer cases and deaths is set to rise substantially from 2024 to 2050, encouragingly, when the global case and mortality rates are adjusted to account for differences in age, they are not forecast to increase. This suggests that most of the increases in cases and deaths will be due to population growth and the rise of ageing populations.
Such improvement, however, is still far away from the ambitious UN Sustainable Development Goal (SDG) to reduce premature mortality due to non-communicable diseases, which include cancer, by a third by 2030.
“Cancer remains an important contributor to disease burden globally and our study highlights how it is anticipated to grow substantially over the coming decades, with disproportionate growth in countries with limited resources,” said lead author Dr Lisa Force from the Institute for Health Metrics and Evaluation (IHME), University of Washington, USA. “Despite the clear need for action, cancer control policies and implementation remain underprioritised in global health, and there is insufficient funding to address this challenge in many settings.”
She added, “Ensuring equitable cancer outcomes globally will require greater efforts to reduce disparities in health service delivery such as access to accurate and timely diagnosis, and quality treatment and supportive care.”
Using data from population-based cancer registries, vital registration systems, and interviews with family members or caregivers of people who have died from cancer, the new analysis provides updated and extended global, regional, and national estimates from 1990 to 2023 in 204 countries and territories for 47 cancer types or groupings and 44 attributable risk factors [1]. The analysis forecasts the cancer burden up to 2050 and examines cancer-specific progress thus far towards the UN SDG to reduce non-communicable disease deaths by a third between 2015 and 2030.
Striking differences in cancer burden around the world
Cancer deaths rose to 10.4 million and new cases jumped to 18.5 million globally in 2023 (both excluding non-melanoma skin cancers)—increases of 74% and 105%, respectively, since 1990 (see summary table 1 at end of release).
However, recent global trends highlight stark disparities in the cancer burden. Although the age-standardised death rates decreased by 24% worldwide between 1990 and 2023, the reduction in rates appears to be driven by high- and upper-middle-income countries. Age-standardised rates of new cases worsened in low-income (up by 24%) and lower-middle-income countries (up by 29%), underscoring the disproportionate growth occurring in settings with lower resources (see table 1 in paper).
Between 1990 and 2023, Lebanon had the greatest percentage increase in age-standardised incidence and mortality rates for both sexes combined, while United Arab Emirates had the greatest decrease in age-standardised incidence, and Kazakhstan had the greatest decrease in age-standardised death rates (see summary table 2 at end of release).
In 2023, breast cancer was the most diagnosed cancer worldwide for both sexes combined, with tracheal, bronchus, and lung (TBL) cancer being the leading cause of cancer deaths (see table 2 in paper).
Increasing impact of behavioural risk factors
The study estimates that 42% (4.3 million) of the estimated 10.4 million cancer deaths in 2023 were attributable to 44 potentially modifiable risk factors—presenting an opportunity for action.
Behavioural risk factors contributed to the most cancer deaths across all country income levels in 2023, especially tobacco use which contributed to 21% of cancer deaths globally. Tobacco was the leading risk factor in all country income levels except low-income countries, where the leading risk factor was unsafe sex (linked to 12.5% of all cancer deaths).
A greater proportion of global cancer deaths in men (46%) in 2023 were linked to potentially modifiable risk factors (mostly tobacco, unhealthy diet, high alcohol use, occupational risks, and air pollution) than in women (36%), for whom the leading risk factors were tobacco, unsafe sex, unhealthy diet, obesity, and high blood sugar (see appendix 2 table 6).
“With four in 10 cancer deaths linked to established risk factors, including tobacco, poor diet, and high blood sugar, there are tremendous opportunities for countries to target these risk factors, potentially preventing cases of cancer and saving lives, alongside improving accurate and early diagnosis and treatment to support individuals who develop cancer,” said co-author Dr Theo Vos from IHME. “Reducing the burden of cancer across countries and worldwide demands both individual action and effective population-level approaches to reduce exposure to known risks.”
Equitable cancer-control efforts must be top priority
Ultimately, the study calls for cancer prevention to be a component of policies in LMICs and underscores the need for equitable cancer-control efforts to ensure all people with cancer receive the care they need where and when they need it.
“The rise of cancer in LMICs is an impending disaster,” said co-author Dr Meghnath Dhimal from the Nepal Health Research Council. “There are cost-effective interventions for cancer in countries at all stages of development. These cancer burden estimates can help broaden the discussion around the importance of cancer and other non-communicable diseases in the global health agenda. To control the growth of non-communicable diseases including cancer in LMICs, an interdisciplinary approach for evidence generation and multi-sectoral collaboration and coordination for implementation are urgently needed."
According to Dr Force, “These new estimates and forecasts can support governments and the global health community in developing data informed policies and actions to improve cancer control and outcomes around the world. They can also support tracking of progress towards global and regional cancer targets.”
She added, “Our analysis also highlights the need for more data from sources such as cancer and vital registries, particularly in lower resource settings. Supporting cancer surveillance systems is crucial to informing both a local and global understanding of cancer burden.”
While the study uses the best available data, the authors note that the estimates are constrained by a lack of high-quality cancer data, particularly in resource-limited countries. They also point out that current GBD estimates do not account for several infectious diseases known to be causally linked to cancers which are common in some lower-income countries such as Helicobacter Pylori and Schistosoma haematobium, which likely underestimates the cancer burden linked to modifiable risks. Neither do they incorporate the impact of the COVID-19 pandemic or recent conflicts on the cancer burden. Finally, estimates of future cancer burden do not account for the impact of potential new breakthrough discoveries that could alter the longer-term trajectory of cancer burden.
Writing in a linked Comment, Dr Qingwei Luo and Dr David P Smith from The University of Sydney and Cancer Council NSW, who were not involved in the study, said: “To ensure meaningful progress in reducing the global cancer burden, it is imperative that governments prioritise funding, strengthen health systems, reduce inequalities, and invest in robust cancer control initiatives and research on prevention, intervention, and implementation—because the future of cancer control depends on decisive, collective action today.”
Summary tables of findings discussed in PR
UI = Uncertainty Interval
ASIR = Age-Standardised Incidence Rate
ASMR = Age-Standardised Mortality Rate
Table 1
Global cancer numbers and rates:
| Cases (millions) | Deaths (millions) | ASIR (per 100,000) | ASMR (per 100,000) |
1990 | 9.04 | 5.95 | 220.6 | 150.7 |
2023 | 18.5 | 10.4 | 205.1 | 114.6 |
2050 | 30.5 | 18.6 | 192.9 | 107.9 |
Table 2
Country cancer rates (more country-level data available via links below):
Country | ASIR (per 100,000) in 1990 | ASIR (per 100,000) in 2023 | ASIR percentage change, 1990 to 2023 | ASMR (per 100,000) in 1990 | ASMR (per 100,000) in 2023 | ASMR percentage change, 1990 to 2023 |
Largest + change ASIR and ASMR (Lebanon) | 89.1 | 233.5 | 162.2 | 65.2 | 117.3 | 80.0 |
Largest - change ASIR (United Arab Emirates) | 234.0 | 102.9 | -56.0 | 201.3 | 87.0 | -56.8 |
Largest - change ASMR (Kazakhstan) | 238.3 | 123.7 | -48.1 | 195.2 | 81.6 | -58.2 |
Australia | 332.4 | 331.1 | -0.4 | 162.0 | 108.3 | -33.2 |
China | 235.1 | 191.7 | -18.5 | 197.9 | 112.5 | -43.2 |
France | 334.5 | 389.4 | 16.4 | 184.7 | 136.8 | -25.9 |
Germany | 317.4 | 328.0 | 3.3 | 178.0 | 133.6 | -24.9 |
India | 84.8 | 107.2 | 26.4 | 71.7 | 86.9 | 21.2 |
Spain | 286.3 | 298.9 | 4.4 | 162.1 | 116.9 | -27.9 |
United Kingdom | 342.9 | 350.3 | 2.2 | 187.1 | 143.4 | -23.4 |
United States of America | 427.7 | 341.5 | -20.2 | 169.3 | 114.2 | -32.5 |
DATA:
- For the ASIRs and ASMRs in 1990 and 2023 for each of the 204 countries see: https://info.thelancet.com/hubfs/Press%20embargo/ASMR%20%2B%20ASIR%20for%20all%20countries%20in%202023%20and%202050.docx.xlsx
- For the top 5 ASMR cancers for each of the 204 countries in 2023 see: https://info.thelancet.com/hubfs/Press%20embargo/Top%205%20cancers%20by%20ASMR%20in%202023.xlsx
- For global rates of the 47 cancer types see table 2 in the paper.
- For enquiries about rates for a specific cancer in a specific country, please contact ihmemedia@uw.edu.
NOTES TO EDITORS
The study was funded by the Gates Foundation, St Jude Children’s Research Hospital, and St Baldrick’s Foundation. It was conducted by the GBD 2023 Cancer Collaborators.
The labels have been added to this press release as part of a project run by the Academy of Medical Sciences seeking to improve the communication of evidence. For more information, please see: http://www.sciencemediacentre.org/wp-content/uploads/2018/01/AMS-press-release-labelling-system-GUIDANCE.pdf if you have any questions or feedback, please contact The Lancet press office pressoffice@lancet.com
[1]
- Level 1: Behavioural, Environmental / Occupational, Metabolic
- Level 2: Air pollution, Dietary risks, Drug use, High alcohol use, High body-mass index, High fasting plasma glucose, Low physical activity, Occupational risks, Other environmental risks, Tobacco, unsafe sex.
- Level 3: Chewing tobacco, Diet high in processed meat, Diet high in red meat, Diet high in sodium, Diet low in calcium, Diet low in fibre, Diet low in fruits, Diet low in milk, Diet low in vegetables, Diet low in whole grains, Occupational carcinogens, Particulate matter pollution, Residential radon, Second-hand smoke, Smoking
- Level 4: Ambient particulate matter pollution, Household air pollution from solid fuels, Occupational exposure to arsenic, Occupational exposure to asbestos, Occupational exposure to benzene, Occupational exposure to beryllium, Occupational exposure to cadmium, Occupational exposure to chromium, Occupational exposure to diesel engine exhaust, Occupational exposure to formaldehyde, Occupational exposure to nickel, Occupational exposure to polycyclic aromatic hydrocarbons, Occupational exposure to silica, Occupational exposure to sulfuric acid, Occupational exposure to trichloroethylene
NOTE: THE ABOVE LINK IS FOR JOURNALISTS ONLY; IF YOU WISH TO PROVIDE A LINK FOR YOUR READERS, PLEASE USE THE FOLLOWING, WHICH WILL GO LIVE AT THE TIME THE EMBARGO LIFTS: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01635-6/fulltext
Journal
The Lancet
Method of Research
Computational simulation/modeling
Subject of Research
People
Article Title
The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023
Article Publication Date
24-Sep-2025
COI Statement
Agostinis Sobrinho reports grants or contracts from the Fundação para a Ciência e a Tecnologia (CEECINST/00093/2021/CP2815/CT0001), outside the submitted work. R Ancuceanu reports consulting fees from AbbVie and Merck Romania; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from AbbVie, Laropharm, Reckitt, and Merck Romania; support for attending meetings or travel from Merck Romania and Reckitt, outside the submitted work. R Bai reports support for this Article from the Social Science Fund of Jiangsu Province (grant number 21GlD008). S Bhaskar reports grants or contracts from the Japan Society for the Promotion of Science (JSPS), Japanese Ministry of Education, Culture, Sports, Science and Technology, Grant-in-Aid for Scientific Research (KAKENHI; grant 23KF0126), JSPS and the Australian Academy of Science, and JSPS International Fellowship (grant P23712); and leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as: district chair of the Diversity, Equity, Inclusion & Belonging of Rotary District 9675 (Sydney, Australia); chair, founding member, and manager of the Global Health & Migration Hub Community, Global Health Hub Germany (Berlin, Germany); editorial board member of PLOS One, BMC Neurology, Frontiers in Neurology, Frontiers in Stroke, Frontiers in Public Health, Journal of Aging Research, and Neurology International, Diagnostics, & BMC Medical Research Methodology; member of the College of Reviewers, Canadian Institutes of Health Research, Government of Canada; Director of Research of World Headache Society (Bengaluru, India); expert adviser and reviewer of Cariplo Foundation (Milan, Italy); visiting director of National Cerebral and Cardiovascular Center, Department of Neurology, Division of Cerebrovascular Medicine and Neurology, Suita (Osaka, Japan); member of the Scientific Review Committee of Cardiff University Biobank (Cardiff, UK); chair of Rotary Reconciliation Action Plan; and Healthcare and Medical Adviser at Japan Connect (Osaka, Japan), outside the submitted work. M Carvalho reports other support from the Laboratório Associado para a Química Verde, University of Porto, Porto, Portugal, under the scope of the project UIDP/50006/2020, outside the submitted work. E C Dee reports support for this Article from the Prostate Cancer Foundation (Young Investigator Award) and the National Cancer Institute (P30 CA008748). A Faro reports support for the this Article from the Brazilian National Council for Scientific and Technological Development. L M Force reports support for this Article from the Gates Foundation, St Jude Children’s Research Hospital, St Baldrick’s Foundation; grants or contracts from Conquer Cancer Foundation, US National Institutes of Health (NIH) Loan Repayment Program; leadership or fiduciary role in other board, society, committee or advocacy group, unpaid with the Lancet Oncology International Advisory Board, outside the submitted work. C Herteliu reports grants or contracts from the project “analysis of the impact of COVID-19 on the main demographic indicators in Romania and the Republic of Moldova by using econometric modeling” (code PN-IV-P8–8·3- ROMD-2023–0208) funded by the Romanian Ministry of Research, Innovation and Digitalization (MCID) through the Executive Agency for Higher Education, Research, Development and Innovation Funding, from a grant of the European Commission Horizon 4P-CAN (personalised cancer primary prevention research through citizen participation and digitally enabled social innovation), grants or contracts from the project “societal and economic resilience within multi-hazards environment in Romania” funded by the EU (NextgenerationEU and Romanian Government), under National Recovery and Resilience Plan for Romania (contract number 760050/ 23.05.2023’ code PNRR-C9-I8-CF 267/ 29.11.2022) through the Romanian Ministry of Research, Innovation and Digitalization, within Component 9, Investment I8, grants or contracts from the project “a better understanding of socio-economic systems using quantitative methods from physics” funded by the EU (NextgenerationEU and Romanian Government), under National Recovery and Resilience Plan for Romania (contract number 760034/ 23.05.2023; code PNRR-C9-I8-CF 255/ 29.11.2022), through the Romanian Ministry of Research, Innovation and Digitalization, within Component 9, Investment I8, outside the submitted work. I Ilic reports support for this Article from the Ministry of Science, Technological Development and Innovation of the Republic of Serbia (number 451–03–137/2025–03/200110). M Ilic reports support for this Article from the Ministry of Science, Technological Development and Innovation of the Republic of Serbia (number 451–03–47/2023–01/200111). T Joo reports support for this Article from National Research, Development and Innovation Office in Hungary (RRF-2.3.1–21–2022–00006, Data-Driven Health Division of National Laboratory for Health Security. J Khubchandani reports grants or contracts from Merck Pharma and the National Science Foundation, outside the submitted work. J Kocarnik reports support for this Article from the Institute for Health Metrics and Evaluation (employee), the Gates Foundation (funding to institution), and the American Lebanese Syrian Associated Charities (funding to institution). A Konstas reports grants or contacts from Thea Pharmaceuticals, Omni Vision, Vianex, Santen, Intermed, and Bayer; consulting fees from Thea Pharmaceuticals and Santen; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Thea Pharmaceuticals, Vianex, Intermed, and Esteve Pharmaceuticals; support for attending meetings or travel from Thea Pharmaceuticals, Vianex, and Intermed, outside the submitted work. K Krishan reports non-financial support from the UGC Centre of Advanced Study, CAS II, awarded to the Department of Anthropology, Panjab University, Chandigarh, India, outside the submitted work. M-C Li reports grants or contracts from the National Science and Technology Council, Taiwan (NSTC 113–2314-B-003–002) and the Higher Education Sprout Project of National Taiwan Normal University, outside the submitted work. W-Z Li reports support for this Article from the Postdoctoral Fellowship Program of China Postdoctoral Science Foundation (GZB20230179) and the Grant of State Key Laboratory of Respiratory Disease (SKLRD-Z-202401). J Liu reports support for this Article from the National Natural Science Foundation (72474005) and Beijing Natural Science Foundation (Z24004). E Lytvyak reports grants or contracts from University of Alberta, Advanz Pharma, WCB Alberta, and China Postdoctoral Science Foundation; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Alberta Obesity Society; other financial or nonfinancial support from University of Alberta and Alberta Health Services, outside the submitted work. H R Marateb reports grants or contracts from Universitat Politècnica de Cataluny, outside the submitted work. D Menges reports grants or contracts from Swiss Cancer Foundation, Dr Arnold U und Susanne Huggenberger–Bischoff Stiftung, one further, private, not-for-profit research foundation from Switzerland (requested anonymity), all outside the submitted work. A-F Mentis reports grants or contracts from “MilkSafe: a novel pipeline to enrich formula milk using omics technologies”, a research cofinanced by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call Research-Create-Innovate (project code T2EDK-02222), as well as from ELIDEK (Hellenic Foundation for Research and Innovation, MIMS-860; both outside of the submitted work); payment or expert testimony as external peer-reviewer for Fondazione Cariplo, Italy; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as editorial board member for Systematic Reviews and Annals of Epidemiology, and as associate editor for Translational Psychiatry, outside the submitted work. S A Meo reports grants or contracts from Ongoing Research Funding Program (ORF-2025–47), King Saud University, Riyadh, Saudi Arabia, outside the submitted work. L Monasta reports support for this Article from the Italian Ministry of Health (Ricerca Corrente 34/2017), payments made to the Institute for Maternal and Child Health IRCCS Burlo Garofolo. S Nomura reports support for this Article from Ministry of Education, Culture, Sports, Science and Technology of Japan (24H00663), Precursory Research for Embryonic Science and Technology from the Japan Science and Technology Agency (JPMJPR22R8), and National Cancer Center Research and Development Fund (2024-A-14). B Oancea reports support for this Article from the Ministry of Research, Innovation and Digitalization through the Core Program of the National Research, Development and Innovation Plan 2022–2027 (project number PN 23–02–0101; contract number 7N/2023, PNRR/2022/C9/MCID/I8 project 760096). F B Omage reports support for this Article from Sao Paulo Research Foundation (Fundacão de Amparo à Pesquisa do Estado de São Paulo; grant number 2023/02691–2). S K Panda reports support for this Article from Siksha ‘O’ Anusandhan (deemed to be University); grants or contracts from File number 17–59/2023–24/CCRH/Tech./Coll./ ICMR-Diabetes/960 as co-investigator; participation on a data safety monitoring board or advisory board as associate editor of Heliyon, outside the submitted work. S Rege reports leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as operational lead of International Society for Pharmacoeconomics and Outcomes Research’s Medication Adherence and Persistence’s Special Interest Group, review editor of Editorial Board of Pharmacoepidemiology section within Frontiers in Pharmacology, Academic Editor of PLOS ONE’s Editorial Board, Editorial Board member of Pain Management, outside the submitted. Y L Samodra reports grants or contracts from National Science and Technology Council, National Taiwan University and College of Public Health, Taipei Medical University; consulting fees from Jago Beasiswa; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as co-founder of Benang Merah Research Center, Indonesia, outside the submitted work. J Sanabria reports support for attending meetings or travel from Continuing Medical Education money from Marshall University School of Medicine, Department of Surgery; patents planned, issued or pending; participation on a data safety monitoring board or advisory board as vice-chair for research and quality assurance; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid with several committees in National and International Societies, outside the submitted work. B M Schaarschmidt reports grants or contracts from Else Kröner-Fresenius Foundation Research, Deutsche Forschungsgemeinschaft, PharmaCept; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca and Boston Scientific; support for attending meetings or travel from Bayer, outside the submitted work. M Šekerija reports consulting fees from Roche; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Astellas, outside the submitted. V Sharma reports other support from Directorate of Forensic Science Services (MHA)’s research project (DFSS28(1)2019/EMR/6) at Institute of Forensic Science & Criminology, Panjab University (Chandigarh, India), outside the submitted work. V Shivarov reports one patent from the Bulgarian Patent Office and other financial support from ICON plc, outside the submitted work. L Silva reports grants or contracts from SPRINT, Sport Physical Activity and Health Research & Innovation Center, Polytechnic of Guarda, 6300–559 Guarda, Portugal; 2RISE-Health, Faculty of Health Sciences, University of Beira Interior, 6201–506 Covilhã, Portugal, outside the submitted work. J A Singh reports consulting fees from ROMTech, Atheneum, Clearview healthcare partners, American College of Rheumatology, Yale, Hulio, Horizon Pharmaceuticals, DINO-RA, ANI/Exeltis, USA, Frictionless Solu-tions, Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two labs, Adept Field Solutions, Clinical Care options, Putnam associates, Focus forward, Navigant consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, and Practice Point communications; and the NIH; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from the bureau of Simply Speaking; support for attending meetings or travel as a past steering committee member of OMERACT; participation on a data safety monitoring board or advisory board from the FDA Arthritis Advisory Committee; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as a past steering committee member of the OMERACT, an international organisation that develops measures for clinical trials and receives arm’s length funding from 12 pharmaceutical companies; stock or stock options in Atai life sciences, Kintara therapeutics, Intelligent Biosolutions, Acumen Pharmaceutical, TPT Global Tech, Vaxart Pharmaceuticals, Atyu Biopharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics, Seres Therapeutics, Tonix Pharmaceuticals Holding, Aebona Pharmaceuticals, and Charlotte’s Web Holdings, and previously owned stock options in Amarin, Viking and Moderna Pharmaceuticals, outside the submitted work. R Tabares-Seisdedos reports grants or contracts from Valencian Regional Government’s Ministry of Education (PROMETEO/CIPROM/2022/58) and from the Spanish Ministry of Science, Innovation and Universities (PID2021–129099OB-I00), outside the submitted work (the funders were not involved in the design of the manuscript or decision to submit the manuscript for publication, nor will they be involved in any aspect of the study’s conduct). J H V Ticoalu reports leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as co-founder of Benang Merah Research Center, Indonesia, outside the submitted work. D Trico reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Eli Lilly, Novo Nordisk; Support for attending meetings or travel from AstraZeneca; participation on a data safety monitoring board or advisory board with Amarin, Boehringer Ingelheim, Novo Nordisk; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid EASD Early Career Academy and EASD Committee on Clinical Affairs; receipt of equipment, materials, drugs, medical writing, gifts or other services paid to the institution from Abbott and PharmaNutra, outside the submitted work. E Vounzoulaki reports grants or contracts from NIHR DSE Award (until July 2026), outside the submitted work. P Willeit reports consulting fees from Novartis Pharmaceuticals, outside the submitted work. J F Wu reports grants or contracts from the National Heart, Lung, and Blood Institute (R38HL167238) and acknowledges previous funding from the American Society of Hematology Hematology Opportunities for the Next Generation of Research Scientists (HONORS) Award, outside the submitted work. S N Zafar reports grants or contracts from the NIH/NCI Early-Stage Surgeon Scientist Program (grant P30 CA014520–48S4), outside the submitted work. M Zielińska reports other support as an Alexion, AstraZeneca Rare Disease employee, outside the submitted work.
